IRB #

STUDY00016649

Title

Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation

Principal Investigator

Emma Scott

Study Purpose

This research study for patients with newly diagnosed Multiple Myeloma (MM) is looking at the safety and effectiveness of a drug, Daratumumab, when added to a standard of care treatment, Revlimid, Velcade, and dexamethasone (RVd) alone. The study is being done primarily to look at whether or not adding daratumumab to standard of care treatment, (RVd), will help patients with newly diagnosed MM achieve a better response after receiving treatment with RVd, with or without daratumumab, and an autologous stem cell transplant (ASCT).

Medical Condition(s)

Newly diagnosed multiple myeloma

Eligibility Criteria

- Men and women 18-70 years of age
- Diagnosed with multiple myeloma
- No previous treatment for your disease

Age Range

18 - 70

Healthy Volunteers Needed

No

Duration of Participation

You will be in the study for approximately 3-4 years, including long-term follow-up.

Minors Included

No

Contact

Clinical Trials Information Line
Phone: 503-494-1080
Email: trials@ohsu.edu

Sponsor

Janssen Biotech, Inc.

Recruitment End

11/08/2020

Compensation Provided

No


Go Back